Nasal Polyps Treatment Market Current Analysis by Market Share 2025-2035

Nasal Polyps Treatment Market Synopsis:

Nasal Polyps Treatment Market Size Was Valued at USD 2871.53 Million in 2024, and is Projected to Reach USD 5239.88 Million by 2035, Growing at a CAGR of 5.62 % from 2025-2035.

The drivers that have led to increased demand for nasal polyps’ treatment are the growing incidence of nasal polyps which are non-cancerous growths that develop in the lining of the nasal passages, or sinuses, as result of inflammation. Some of these may cause symptoms like; having a blocked nose, loss of smell, and sinusitis that calls for proper treatment. There are such therapies as corticosteroids, nasal decongestants, and biologics for cases when conservative treatment is ineffective; surgical intervention is also possible. An increased level of health knowledge concerning the existence of nasal polyps along with the recent developments in medical care is also expected to increase demand for the product.

Biologic therapy which includes antibodies have taken centre stage in the treatment of nasal polyps and it has offered patients a much-improved way of treatment. These biologics including dupilumab have been proved to decreased inflammation, and also control the size of the polyps thus enhancing the quality of life among the individuals. Moreover, the increase in prevalence for chronic respiratory diseases like asthma and rhinosinusitis, which can also develop polyps, also exaggerates the need for advanced polyp treatments. With increased research, it is anticipated that there might be innovation on the formulations and the method of delivering nasal polyps treatment localized in the nasal cavity

Regional wise markets North America, is dominating nasal polyp’s treatment market due to well established healthcare facilities, high expenditure of healthcare and inclining prevails towards advanced treatment. Asia-Pacific region is predicted to grow fast due to increasing healthcare demand, increasing consciousness, and a developing population. The market is also encouraged by the rising health care spending and more efforts being made to improve on methods of diagnosing and treating nasal polyps early in advance so that they will have little or no impact on patients and healthcare systems globally.

Nasal Polyps Treatment Market Trend Analysis:

Growing Adoption of Biologic Therapies

• Nasal polyp’s treatment market is experiencing rapid transformation in preference to biologic therapy especially monoclonal antibodies including dupilumab. These therapies work to directly on point inflammatory mediators that are relevant to development and growth of nasal polyps, provide higher efficacy and patient orientated approach to the treatment for this pathology. Biologics can be beneficial for treatment of inflammatory diseases, decreasing size and number of polyps, enhancing nasal patency and demonstrating substantial long-term effectiveness, that is why they are used for chronic diseases such as asthma and rhinosinusitis. It is anticipated that this will increase in the coming years, primarily due to increasing discovery of biologic therapies together with further integration of biologics nowadays.

Advancements in Minimally Invasive Surgical Procedures

• Apart from medications, there has also rise in conservative surgical operations to get rid of nasal polyps. The method like ESS and balloon sinuplasty is hotting up for it gives shorter recovery period than the conventional form of surgery. These procedures make it possible to treat the nasal polyps, and at the same time reduce the consequences of the operation on the surrounding tissues leading to improved health of the patients. Since the use of technology in operations is constant, the need for such operations the provides minimum invasion to the body will increase as a supplement to medical treatments to the polyp affected individuals.

Nasal Polyps Treatment Market Segment Analysis:

Nasal Polyps Treatment Market is Segmented on the basis of type, related diseases, treatment complications, drug class, diagnosis, treatment, medication, route of administration, end users, distribution channel, and region

By Type, Ethmoidal Polyp segment is expected to dominate the market during the forecast period

• The nasal polyp’s treatment market based on the type has ethmoidal polyp, antrochoanal polyp, and others. Ethmoidal polyps developing from the ethmoid sinus are the most frequent type of nasal polyps and usually cannot be treated with conservative therapy that includes steroids or biologics but may require surgery. Antrochoanal polyps, which are benign tumours more often situated in the maxillary sinuses, can be treated only by surgical removal. The other category consists in a number of less frequent polyps which may be treated in different ways depending on the size, location, and etiology. Therapies of all types are gradually focused on the individual, and have medical and surgical methods aimed at relieving symptoms and enhancing patients’ quality of life.

By Distribution Channel, Agricultural segment expected to held the largest share

• The distribution channels for the nasal polyp’s treatment market work help in making sure that patients get to obtain appropriate medication and proceeds to therapy. While receiving treatment in health-care entity/ facility, hospital pharmacy plays a crucial role of dispensing the required prescribed medicine like biologic therapies and corticosteroids. Online pharmacy has also gained popularity among consumers as a way of making their order some medications from the comfort of their homes especially for recurrent medication or maintenance medications. Retail pharmacies are convenient and available for every patient; they should continue to supply both over-the-counter nasal sprays and decongestants for uncomplicated flu cases while other distribution systems include clinics, specialty pharmacies and the like. The diverse distribution channels are useful in guaranteeing that the nasal polyps’ treatments are available throughout group the different patients and areas.

Nasal Polyps Treatment Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• North America will continue to have the largest market share in the nasal polyp’s treatment during the forecast period because chronic sinusitis and allergic rhinitis, key risk factors of nasal polyps, are on the rise in the region. This area has benefitted from highly developed health facilities, high average annual health care costs, and a robust research and development, especially in biotechnology products andless invasive surgery fields. Also, increased understanding of nasal polyps and new treatment options like biologic are factors which contribute to the growth of this market in North America. The presence of major pharmaceutical industries and rising trend towards targeted therapy adds to the regions’ market success.

Active Key Players in the Nasal Polyps Treatment Market

• Abbott (U.S.)
• Sanofi (France)
• AstraZeneca (U.K.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Johnson & Johnson Services, Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Novartis International AG (Switzerland)
• GSK plc (U.K.)
• Bayer AG (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Cipla Ltd. (India)
• Mylan N.V. (U.S.)
• Merck KGaA (Germany), and other active players.

Key Industry Developments in the Nasal Polyps Treatment Market:

• In January 2025, GSK plc announced that China’s National Medical Products Administration approved Nucala (mepolizumab), a monoclonal antibody targeting interleukin-5 (IL-5), as an add-on therapy for adults with chronic rhinosinusitis with nasal polyps (CRSwNP). The treatment is indicated for patients who do not achieve adequate disease control with systemic corticosteroids and/or surgery. This approval marks a significant step in addressing unmet needs for CRSwNP patients in China.

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Nasal Polyps Treatment Market by Type (2018-2035)
 4.1 Nasal Polyps Treatment Market Snapshot and Growth Engine
 4.2 Market Overview
 4.3 Ethmoidal Polyp
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
  4.3.3 Key Market Trends, Growth Factors, and Opportunities
  4.3.4 Geographic Segmentation Analysis
 4.4 Antrochoanal Polyp
 4.5 Others
 4.6 Related Diseases
 4.7 Chronic Sinusitis
 4.8 Cystic Fibrosis (CF)
 4.9 Allergic Fungal Sinusitis (AFS)
 4.10 Others

Chapter 5: Nasal Polyps Treatment Market by Treatment (2018-2035)
 5.1 Nasal Polyps Treatment Market Snapshot and Growth Engine
 5.2 Market Overview
 5.3 Pharmacological Therapies
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
  5.3.3 Key Market Trends, Growth Factors, and Opportunities
  5.3.4 Geographic Segmentation Analysis
 5.4 Surgeries
 5.5 Complications
 5.6 Obstructive Sleep Apnea
 5.7 Sinus Infections
 5.8 Others

Chapter 6: Nasal Polyps Treatment Market by Drug Class (2018-2035)
 6.1 Nasal Polyps Treatment Market Snapshot and Growth Engine
 6.2 Market Overview
 6.3 Corticosteroids
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
  6.3.3 Key Market Trends, Growth Factors, and Opportunities
  6.3.4 Geographic Segmentation Analysis
 6.4 Antibiotics
 6.5 Leukotriene Inhibitors
 6.6 Others

Chapter 7: Nasal Polyps Treatment Market by Diagnosis (2018-2035)
 7.1 Nasal Polyps Treatment Market Snapshot and Growth Engine
 7.2 Market Overview
 7.3 Nasal Endoscopy
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
  7.3.3 Key Market Trends, Growth Factors, and Opportunities
  7.3.4 Geographic Segmentation Analysis
 7.4 Blood Test
 7.5 Allergy Tests
 7.6 Others

Chapter 8: Nasal Polyps Treatment Market by Treatment (2018-2035)
 8.1 Nasal Polyps Treatment Market Snapshot and Growth Engine
 8.2 Market Overview
 8.3 Medication
  8.3.1 Introduction and Market Overview
  8.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
  8.3.3 Key Market Trends, Growth Factors, and Opportunities
  8.3.4 Geographic Segmentation Analysis
 8.4 Surgery
 8.5 Others
 8.6 Medication
 8.7 Nasal Corticosteroids
 8.8 Medication to Treat Nasal Polyps and Chronic Sinusitis
 8.9 Others

Chapter 9: Nasal Polyps Treatment Market by Route of Administration (2018-2035)
 9.1 Nasal Polyps Treatment Market Snapshot and Growth Engine
 9.2 Market Overview
 9.3 Oral
  9.3.1 Introduction and Market Overview
  9.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
  9.3.3 Key Market Trends, Growth Factors, and Opportunities
  9.3.4 Geographic Segmentation Analysis
 9.4 Injectable
 9.5 Others

Chapter 10: Nasal Polyps Treatment Market by End Users (2018-2035)
 10.1 Nasal Polyps Treatment Market Snapshot and Growth Engine
 10.2 Market Overview
 10.3 Hospitals
  10.3.1 Introduction and Market Overview
  10.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
  10.3.3 Key Market Trends, Growth Factors, and Opportunities
  10.3.4 Geographic Segmentation Analysis
 10.4 Homecare
 10.5 Specialty Clinics
 10.6 Others

Chapter 11: Nasal Polyps Treatment Market by Distribution Channel (2018-2035)
 11.1 Nasal Polyps Treatment Market Snapshot and Growth Engine
 11.2 Market Overview
 11.3 Hospital Pharmacy
  11.3.1 Introduction and Market Overview
  11.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
  11.3.3 Key Market Trends, Growth Factors, and Opportunities
  11.3.4 Geographic Segmentation Analysis
 11.4 Online Pharmacy
 11.5 Retail Pharmacy
 11.6 Others

Chapter 12: Company Profiles and Competitive Analysis
 12.1 Competitive Landscape
  12.1.1 Competitive Benchmarking
  12.1.2 Nasal Polyps Treatment Market Share by Manufacturer (2024)
  12.1.3 Industry BCG Matrix
  12.1.4 Heat Map Analysis
  12.1.5 Mergers and Acquisitions  
 12.2 ABBOTT (U.S.)
  12.2.1 Company Overview
  12.2.2 Key Executives
  12.2.3 Company Snapshot
  12.2.4 Role of the Company in the Market
  12.2.5 Sustainability and Social Responsibility
  12.2.6 Operating Business Segments
  12.2.7 Product Portfolio
  12.2.8 Business Performance
  12.2.9 Key Strategic Moves and Recent Developments
  12.2.10 SWOT Analysis
 12.3 SANOFI (FRANCE)
 12.4 ASTRAZENECA (U.K.)
 12.5 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
 12.6 JOHNSON & JOHNSON SERVICES INC. (U.S.)
 12.7 PFIZER INC. (U.S.)
 12.8 NOVARTIS INTERNATIONAL AG (SWITZERLAND)
 12.9 GSK PLC (U.K.)
 12.10 BAYER AG (GERMANY)
 12.11 SUN PHARMACEUTICAL INDUSTRIES LTD. (INDIA)
 12.12 CIPLA LTD. (INDIA)
 12.13 MYLAN N.V. (U.S.)
 12.14 MERCK KGAA (GERMANY)
 12.15 OTHER ACTIVE PLAYERS.

Chapter 13: Global Nasal Polyps Treatment Market By Region
 13.1 Overview
 13.2. North America Nasal Polyps Treatment Market
  13.2.1 Key Market Trends, Growth Factors and Opportunities
  13.2.2 Top Key Companies
  13.2.3 Historic and Forecasted Market Size by Segments
  13.2.4 Historic and Forecasted Market Size by Type
  13.2.4.1 Ethmoidal Polyp
  13.2.4.2 Antrochoanal Polyp
  13.2.4.3 Others
  13.2.4.4 Related Diseases
  13.2.4.5 Chronic Sinusitis
  13.2.4.6 Cystic Fibrosis (CF)
  13.2.4.7 Allergic Fungal Sinusitis (AFS)
  13.2.4.8 Others
  13.2.5 Historic and Forecasted Market Size By Treatment
  13.2.5.1 Pharmacological Therapies
  13.2.5.2 Surgeries
  13.2.5.3 Complications
  13.2.5.4 Obstructive Sleep Apnea
  13.2.5.5 Sinus Infections
  13.2.5.6 Others
  13.2.6 Historic and Forecasted Market Size By Drug Class
  13.2.6.1 Corticosteroids
  13.2.6.2 Antibiotics
  13.2.6.3 Leukotriene Inhibitors
  13.2.6.4 Others
  13.2.7 Historic and Forecasted Market Size By Diagnosis
  13.2.7.1 Nasal Endoscopy
  13.2.7.2 Blood Test
  13.2.7.3 Allergy Tests
  13.2.7.4 Others
  13.2.8 Historic and Forecasted Market Size By Treatment
  13.2.8.1 Medication
  13.2.8.2 Surgery
  13.2.8.3 Others
  13.2.8.4 Medication
  13.2.8.5 Nasal Corticosteroids
  13.2.8.6 Medication to Treat Nasal Polyps and Chronic Sinusitis
  13.2.8.7 Others
  13.2.9 Historic and Forecasted Market Size By Route of Administration
  13.2.9.1 Oral
  13.2.9.2 Injectable
  13.2.9.3 Others
  13.2.10 Historic and Forecasted Market Size By End Users
  13.2.10.1 Hospitals
  13.2.10.2 Homecare
  13.2.10.3 Specialty Clinics
  13.2.10.4 Others
  13.2.11 Historic and Forecasted Market Size By Distribution Channel
  13.2.11.1 Hospital Pharmacy
  13.2.11.2 Online Pharmacy
  13.2.11.3 Retail Pharmacy
  13.2.11.4 Others
  13.2.12 Historic and Forecast Market Size by Country
  13.2.12.1 US
  13.2.12.2 Canada
  13.2.12.3 Mexico
 13.3. Eastern Europe Nasal Polyps Treatment Market
  13.3.1 Key Market Trends, Growth Factors and Opportunities
  13.3.2 Top Key Companies
  13.3.3 Historic and Forecasted Market Size by Segments
  13.3.4 Historic and Forecasted Market Size by Type
  13.3.4.1 Ethmoidal Polyp
  13.3.4.2 Antrochoanal Polyp
  13.3.4.3 Others
  13.3.4.4 Related Diseases
  13.3.4.5 Chronic Sinusitis
  13.3.4.6 Cystic Fibrosis (CF)
  13.3.4.7 Allergic Fungal Sinusitis (AFS)
  13.3.4.8 Others
  13.3.5 Historic and Forecasted Market Size By Treatment
  13.3.5.1 Pharmacological Therapies
  13.3.5.2 Surgeries
  13.3.5.3 Complications
  13.3.5.4 Obstructive Sleep Apnea
  13.3.5.5 Sinus Infections
  13.3.5.6 Others
  13.3.6 Historic and Forecasted Market Size By Drug Class
  13.3.6.1 Corticosteroids
  13.3.6.2 Antibiotics
  13.3.6.3 Leukotriene Inhibitors
  13.3.6.4 Others
  13.3.7 Historic and Forecasted Market Size By Diagnosis
  13.3.7.1 Nasal Endoscopy
  13.3.7.2 Blood Test
  13.3.7.3 Allergy Tests
  13.3.7.4 Others
  13.3.8 Historic and Forecasted Market Size By Treatment
  13.3.8.1 Medication
  13.3.8.2 Surgery
  13.3.8.3 Others
  13.3.8.4 Medication
  13.3.8.5 Nasal Corticosteroids
  13.3.8.6 Medication to Treat Nasal Polyps and Chronic Sinusitis
  13.3.8.7 Others
  13.3.9 Historic and Forecasted Market Size By Route of Administration
  13.3.9.1 Oral
  13.3.9.2 Injectable
  13.3.9.3 Others
  13.3.10 Historic and Forecasted Market Size By End Users
  13.3.10.1 Hospitals
  13.3.10.2 Homecare
  13.3.10.3 Specialty Clinics
  13.3.10.4 Others
  13.3.11 Historic and Forecasted Market Size By Distribution Channel
  13.3.11.1 Hospital Pharmacy
  13.3.11.2 Online Pharmacy
  13.3.11.3 Retail Pharmacy
  13.3.11.4 Others
  13.3.12 Historic and Forecast Market Size by Country
  13.3.12.1 Russia
  13.3.12.2 Bulgaria
  13.3.12.3 The Czech Republic
  13.3.12.4 Hungary
  13.3.12.5 Poland
  13.3.12.6 Romania
  13.3.12.7 Rest of Eastern Europe
 13.4. Western Europe Nasal Polyps Treatment Market
  13.4.1 Key Market Trends, Growth Factors and Opportunities
  13.4.2 Top Key Companies
  13.4.3 Historic and Forecasted Market Size by Segments
  13.4.4 Historic and Forecasted Market Size by Type
  13.4.4.1 Ethmoidal Polyp
  13.4.4.2 Antrochoanal Polyp
  13.4.4.3 Others
  13.4.4.4 Related Diseases
  13.4.4.5 Chronic Sinusitis
  13.4.4.6 Cystic Fibrosis (CF)
  13.4.4.7 Allergic Fungal Sinusitis (AFS)
  13.4.4.8 Others
  13.4.5 Historic and Forecasted Market Size By Treatment
  13.4.5.1 Pharmacological Therapies
  13.4.5.2 Surgeries
  13.4.5.3 Complications
  13.4.5.4 Obstructive Sleep Apnea
  13.4.5.5 Sinus Infections
  13.4.5.6 Others
  13.4.6 Historic and Forecasted Market Size By Drug Class
  13.4.6.1 Corticosteroids
  13.4.6.2 Antibiotics
  13.4.6.3 Leukotriene Inhibitors
  13.4.6.4 Others
  13.4.7 Historic and Forecasted Market Size By Diagnosis
  13.4.7.1 Nasal Endoscopy
  13.4.7.2 Blood Test
  13.4.7.3 Allergy Tests
  13.4.7.4 Others
  13.4.8 Historic and Forecasted Market Size By Treatment
  13.4.8.1 Medication
  13.4.8.2 Surgery
  13.4.8.3 Others
  13.4.8.4 Medication
  13.4.8.5 Nasal Corticosteroids
  13.4.8.6 Medication to Treat Nasal Polyps and Chronic Sinusitis
  13.4.8.7 Others
  13.4.9 Historic and Forecasted Market Size By Route of Administration
  13.4.9.1 Oral
  13.4.9.2 Injectable
  13.4.9.3 Others
  13.4.10 Historic and Forecasted Market Size By End Users
  13.4.10.1 Hospitals
  13.4.10.2 Homecare
  13.4.10.3 Specialty Clinics
  13.4.10.4 Others
  13.4.11 Historic and Forecasted Market Size By Distribution Channel
  13.4.11.1 Hospital Pharmacy
  13.4.11.2 Online Pharmacy
  13.4.11.3 Retail Pharmacy
  13.4.11.4 Others
  13.4.12 Historic and Forecast Market Size by Country
  13.4.12.1 Germany
  13.4.12.2 UK
  13.4.12.3 France
  13.4.12.4 The Netherlands
  13.4.12.5 Italy
  13.4.12.6 Spain
  13.4.12.7 Rest of Western Europe
 13.5. Asia Pacific Nasal Polyps Treatment Market
  13.5.1 Key Market Trends, Growth Factors and Opportunities
  13.5.2 Top Key Companies
  13.5.3 Historic and Forecasted Market Size by Segments
  13.5.4 Historic and Forecasted Market Size by Type
  13.5.4.1 Ethmoidal Polyp
  13.5.4.2 Antrochoanal Polyp
  13.5.4.3 Others
  13.5.4.4 Related Diseases
  13.5.4.5 Chronic Sinusitis
  13.5.4.6 Cystic Fibrosis (CF)
  13.5.4.7 Allergic Fungal Sinusitis (AFS)
  13.5.4.8 Others
  13.5.5 Historic and Forecasted Market Size By Treatment
  13.5.5.1 Pharmacological Therapies
  13.5.5.2 Surgeries
  13.5.5.3 Complications
  13.5.5.4 Obstructive Sleep Apnea
  13.5.5.5 Sinus Infections
  13.5.5.6 Others
  13.5.6 Historic and Forecasted Market Size By Drug Class
  13.5.6.1 Corticosteroids
  13.5.6.2 Antibiotics
  13.5.6.3 Leukotriene Inhibitors
  13.5.6.4 Others
  13.5.7 Historic and Forecasted Market Size By Diagnosis
  13.5.7.1 Nasal Endoscopy
  13.5.7.2 Blood Test
  13.5.7.3 Allergy Tests
  13.5.7.4 Others
  13.5.8 Historic and Forecasted Market Size By Treatment
  13.5.8.1 Medication
  13.5.8.2 Surgery
  13.5.8.3 Others
  13.5.8.4 Medication
  13.5.8.5 Nasal Corticosteroids
  13.5.8.6 Medication to Treat Nasal Polyps and Chronic Sinusitis
  13.5.8.7 Others
  13.5.9 Historic and Forecasted Market Size By Route of Administration
  13.5.9.1 Oral
  13.5.9.2 Injectable
  13.5.9.3 Others
  13.5.10 Historic and Forecasted Market Size By End Users
  13.5.10.1 Hospitals
  13.5.10.2 Homecare
  13.5.10.3 Specialty Clinics
  13.5.10.4 Others
  13.5.11 Historic and Forecasted Market Size By Distribution Channel
  13.5.11.1 Hospital Pharmacy
  13.5.11.2 Online Pharmacy
  13.5.11.3 Retail Pharmacy
  13.5.11.4 Others
  13.5.12 Historic and Forecast Market Size by Country
  13.5.12.1 China
  13.5.12.2 India
  13.5.12.3 Japan
  13.5.12.4 South Korea
  13.5.12.5 Malaysia
  13.5.12.6 Thailand
  13.5.12.7 Vietnam
  13.5.12.8 The Philippines
  13.5.12.9 Australia
  13.5.12.10 New Zealand
  13.5.12.11 Rest of APAC
 13.6. Middle East & Africa Nasal Polyps Treatment Market
  13.6.1 Key Market Trends, Growth Factors and Opportunities
  13.6.2 Top Key Companies
  13.6.3 Historic and Forecasted Market Size by Segments
  13.6.4 Historic and Forecasted Market Size by Type
  13.6.4.1 Ethmoidal Polyp
  13.6.4.2 Antrochoanal Polyp
  13.6.4.3 Others
  13.6.4.4 Related Diseases
  13.6.4.5 Chronic Sinusitis
  13.6.4.6 Cystic Fibrosis (CF)
  13.6.4.7 Allergic Fungal Sinusitis (AFS)
  13.6.4.8 Others
  13.6.5 Historic and Forecasted Market Size By Treatment
  13.6.5.1 Pharmacological Therapies
  13.6.5.2 Surgeries
  13.6.5.3 Complications
  13.6.5.4 Obstructive Sleep Apnea
  13.6.5.5 Sinus Infections
  13.6.5.6 Others
  13.6.6 Historic and Forecasted Market Size By Drug Class
  13.6.6.1 Corticosteroids
  13.6.6.2 Antibiotics
  13.6.6.3 Leukotriene Inhibitors
  13.6.6.4 Others
  13.6.7 Historic and Forecasted Market Size By Diagnosis
  13.6.7.1 Nasal Endoscopy
  13.6.7.2 Blood Test
  13.6.7.3 Allergy Tests
  13.6.7.4 Others
  13.6.8 Historic and Forecasted Market Size By Treatment
  13.6.8.1 Medication
  13.6.8.2 Surgery
  13.6.8.3 Others
  13.6.8.4 Medication
  13.6.8.5 Nasal Corticosteroids
  13.6.8.6 Medication to Treat Nasal Polyps and Chronic Sinusitis
  13.6.8.7 Others
  13.6.9 Historic and Forecasted Market Size By Route of Administration
  13.6.9.1 Oral
  13.6.9.2 Injectable
  13.6.9.3 Others
  13.6.10 Historic and Forecasted Market Size By End Users
  13.6.10.1 Hospitals
  13.6.10.2 Homecare
  13.6.10.3 Specialty Clinics
  13.6.10.4 Others
  13.6.11 Historic and Forecasted Market Size By Distribution Channel
  13.6.11.1 Hospital Pharmacy
  13.6.11.2 Online Pharmacy
  13.6.11.3 Retail Pharmacy
  13.6.11.4 Others
  13.6.12 Historic and Forecast Market Size by Country
  13.6.12.1 Turkiye
  13.6.12.2 Bahrain
  13.6.12.3 Kuwait
  13.6.12.4 Saudi Arabia
  13.6.12.5 Qatar
  13.6.12.6 UAE
  13.6.12.7 Israel
  13.6.12.8 South Africa
 13.7. South America Nasal Polyps Treatment Market
  13.7.1 Key Market Trends, Growth Factors and Opportunities
  13.7.2 Top Key Companies
  13.7.3 Historic and Forecasted Market Size by Segments
  13.7.4 Historic and Forecasted Market Size by Type
  13.7.4.1 Ethmoidal Polyp
  13.7.4.2 Antrochoanal Polyp
  13.7.4.3 Others
  13.7.4.4 Related Diseases
  13.7.4.5 Chronic Sinusitis
  13.7.4.6 Cystic Fibrosis (CF)
  13.7.4.7 Allergic Fungal Sinusitis (AFS)
  13.7.4.8 Others
  13.7.5 Historic and Forecasted Market Size By Treatment
  13.7.5.1 Pharmacological Therapies
  13.7.5.2 Surgeries
  13.7.5.3 Complications
  13.7.5.4 Obstructive Sleep Apnea
  13.7.5.5 Sinus Infections
  13.7.5.6 Others
  13.7.6 Historic and Forecasted Market Size By Drug Class
  13.7.6.1 Corticosteroids
  13.7.6.2 Antibiotics
  13.7.6.3 Leukotriene Inhibitors
  13.7.6.4 Others
  13.7.7 Historic and Forecasted Market Size By Diagnosis
  13.7.7.1 Nasal Endoscopy
  13.7.7.2 Blood Test
  13.7.7.3 Allergy Tests
  13.7.7.4 Others
  13.7.8 Historic and Forecasted Market Size By Treatment
  13.7.8.1 Medication
  13.7.8.2 Surgery
  13.7.8.3 Others
  13.7.8.4 Medication
  13.7.8.5 Nasal Corticosteroids
  13.7.8.6 Medication to Treat Nasal Polyps and Chronic Sinusitis
  13.7.8.7 Others
  13.7.9 Historic and Forecasted Market Size By Route of Administration
  13.7.9.1 Oral
  13.7.9.2 Injectable
  13.7.9.3 Others
  13.7.10 Historic and Forecasted Market Size By End Users
  13.7.10.1 Hospitals
  13.7.10.2 Homecare
  13.7.10.3 Specialty Clinics
  13.7.10.4 Others
  13.7.11 Historic and Forecasted Market Size By Distribution Channel
  13.7.11.1 Hospital Pharmacy
  13.7.11.2 Online Pharmacy
  13.7.11.3 Retail Pharmacy
  13.7.11.4 Others
  13.7.12 Historic and Forecast Market Size by Country
  13.7.12.1 Brazil
  13.7.12.2 Argentina
  13.7.12.3 Rest of SA

Chapter 14 Analyst Viewpoint and Conclusion
14.1 Recommendations and Concluding Analysis
14.2 Potential Market Strategies

Chapter 15 Research Methodology
15.1 Research Process
15.2 Primary Research
15.3 Secondary Research